The largest database of trusted experimental protocols

6 protocols using recombinant human gdf15

1

Recombinant GDF15 Cytotoxicity Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant human GDF15 (R&D Systems, Minneapolis, MN, catalogue number 957-GD-025) was resuspended in water at 10ug/uL. Knockout with sgGREP1 #2 or controls in ZR-75–1 was performed as described above. 24 hours after infection with lentiviral sgRNA, cell culture media was refreshed to contain puromycin as above for antibiotic selection, and GDF15 or vehicle control was supplemented at the following concentrations: 0.01 pg/mL, 0.1 pg/mL, 1pg/mL, 10pg/mL, 100pg/mL. Thereafter cell culture media and recombinant GDF15 was refreshed every 24 hours. Cell viability was measured 7 days after lentiviral infection using the CellTiter-Glo reagent (Promega, Madison, WI).
+ Open protocol
+ Expand
2

Signaling Pathway Modulation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
SB431542, PD98059, SB203580, SB202190, oligomycin, carbonyl cyanide m-chlorophenyl hydrazone (CCCP) were from Sigma-Aldrich (St. Louis, MO, USA). Recombinant human GDF15 containing an N-terminal 6-His tag was purchased from R&D Systems (#957-GD/CF). Lyophilized protein was reconstituted with sterile 4 mM HCl and stored at −70 °C.
+ Open protocol
+ Expand
3

Biomarker Quantification in Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum concentrations of PLGF, GDF15 and HGF were determined in 834 patients. PLGF was tested using electrochemiluminescence test (ELECSYS PlGF, Roche Diagnostics, Mannheim, Germany). HGF was analysed using the enzyme-linked immunoassay obtained from R&D Systems (Minneapolis, USA), using a monoclonal antibody specific for HGF and a pre-coated microtiter plate. GDF15 was tested using a prototype electrochemiluminescence test containing a polyclonal GDF15 affinity chromatography-purified goat anti-human IgG antibody obtained from R&D Systems. For each of the measurement sets, a standard curve was generated with recombinant human GDF15 from R&D Systems.
+ Open protocol
+ Expand
4

Molecular Signaling Pathways in Stem Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant human GDF15 (R&D Systems, Minneapolis, MN, USA), imiquimod (IMQ, InvivoGen, San Diego, CA, USA), neutralizing antibody against LIF (R&D Systems), and ERK1/2 inhibitor PD98059 (Cell Signaling Technology, Danvers, MA, USA) were used in this study. The antibodies used were as follows: anti-CD133/2 (Miltenyi Biotec, Auburn, CA, USA), anti-PROM1 (Sigma Aldrich, St. Louis, MO, USA), anti-Nestin (Merck-Millipore, Billerica, MA, USA), anti-Toll-like receptor 7 (anti-TLR7, Novus Biological Inc., Littleton, CO, USA), anti-Musashi (Merck-Millipore), anti-phospho-STAT3 (p-Tyr705, Cell Signaling Technology), anti-STAT3 (Thermo Fisher Scientific), anti-SOX2 (R&D Systems), anti-ALDH1 (Thermo Fisher Scientific), anti-β-actin (TransGen Biotech, Beijing, China), anti-GDF15 (Thermo Fisher Scientific), anti-LIF (Merck-Millipore), and anti-Fos (GeneTex, Irvine, CA, USA). The Smad2/3 Antibody Sampler Kit (Cell Signaling Technology) and Smad1/5/9 Antibody Sampler Kit (Cell Signaling Technology) were also employed.
+ Open protocol
+ Expand
5

Cardioprotective Effects of Factor 1 against Ischemia-Reperfusion Injury

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 3

To confirm the cardiomyocyte-protective effects of Factor 1 observed in the screen, neonatal rat ventricular cardiomyocytes were subjected to simulated ischemia-reperfusion injury in the presence or absence of recombinant Factor 1. Factor 1 (mouse homologue encoded by the nucleic acid sequence shown in SEQ ID NO: 7) was produced in COS7 cells as a His-tagged recombinant protein. As shown in FIG. 2, recombinant Factor 1 promoted dose-dependent anti-apoptotic effects in cultured cardiomyocytes.

Ventricular cardiomyocytes were isolated from 1 to 3-day-old Sprague-Dawley rats by Percoll density gradient centrifugation. Cardiomyocytes were exposed to simulated ischemia for 180 min (glucose-free medium containing 2-deoxyglucose in 5% CO2/95% N2 atmosphere) followed by simulated reperfusion for 60 min (back to glucose-containing medium in 5% CO2/95% room air) in the absence (control) or presence of recombinant human GDF-15 (R&D Systems, known anti-apoptotic cytokine) or different concentrations of recombinant mouse Factor 1, as indicated. Cell death was assessed by in situ TdT-mediated dUTP nick end-labeling (TUNEL). N=3 independent experiments per condition; *P<0.05 vs. control.

+ Open protocol
+ Expand
6

Cisplatin, Doxorubicin, and Thalidomide Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cisplatin, doxorubicin, and thalidomide were obtained from Sigma‐Aldrich (St. Louis, MO). Recombinant human GDF15 was purchased from R&D Systems (Minneapolis, MN). Polyclonal rabbit anti‐human ERK1/2 antibody, polyclonal rabbit anti‐human p38 MAPK antibody, monoclonal rabbit anti‐human JNK antibody, monoclonal rabbit anti‐human P‐JNK antibody, polyclonal goat anti‐human GDF15 antibody and polyclonal rabbit anti‐human NF‐κB antibody (Abcam, Cambridge, UK), polyclonal rabbit anti‐human P‐ERK1/2 antibody (Thermo Fisher Scientific, Waltham, MA, USA), monoclonal mouse anti‐human P‐P38MAPK antibody, monoclonal rabbit anti‐human Akt antibody, monoclonal rabbit anti‐human P‐Akt antibody, polyclonal rabbit anti‐human Src antibody, polyclonal rabbit anti‐human p‐Src antibody, and monoclonal rabbit anti‐human p‐NF‐κB antibody (Cell Signaling Technology, Beverly, MA) were used for Western blots. Monoclonal rabbit anti‐human CD31 antibody and polyclonal rabbit anti‐human paxillin antibody (Abcam, Cambridge, UK) were used for immunohistochemical analysis and immunofluorescence, respectively. Src inhibitor Saracatinib was purchased from Selleckchem (Houston, TX).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!